Bayer Long-Term Investments 2010-2024 | BAYRY

Bayer long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Bayer Annual Long-Term Investments
(Millions of US $)
2023 $3,374
2022 $3,100
2021 $3,141
2020 $2,337
2019 $2,305
2018 $3,221
2017 $6,376
2016 $2,064
2015 $1,486
2014 $1,768
2013 $1,868
2012 $2,068
2011 $444
2010 $470
2009 $551
Bayer Quarterly Long-Term Investments
(Millions of US $)
2024-06-30 $3,423
2024-03-31 $3,476
2023-12-31 $3,374
2023-09-30 $3,070
2023-06-30 $3,050
2023-03-31 $3,012
2022-12-31 $3,100
2022-09-30 $2,958
2022-06-30 $2,971
2022-03-31 $3,004
2021-12-31 $3,141
2021-09-30 $2,687
2021-06-30 $2,652
2021-03-31 $2,703
2020-12-31 $2,337
2020-09-30 $2,421
2020-06-30 $2,226
2020-03-31 $2,306
2019-12-31 $2,305
2019-09-30 $3,264
2019-06-30 $3,210
2019-03-31 $3,175
2018-12-31 $3,221
2018-09-30 $3,679
2018-06-30 $3,955
2018-03-31 $5,299
2017-12-31 $6,376
2017-09-30 $2,180
2017-06-30 $2,145
2017-03-31 $1,749
2016-12-31 $2,064
2016-09-30 $2,070
2016-06-30 $2,034
2016-03-31 $1,952
2015-12-31 $1,486
2015-09-30 $1,458
2015-06-30 $1,522
2015-03-31 $1,656
2014-12-31 $1,768
2014-09-30 $1,874
2014-06-30 $2,010
2014-03-31 $1,961
2013-12-31 $1,868
2013-09-30 $1,857
2013-06-30 $1,950
2013-03-31 $1,989
2012-12-31 $2,068
2012-09-30 $2,060
2012-06-30 $2,227
2012-03-31 $2,199
2011-12-31 $444
2011-09-30 $452
2011-06-30 $453
2011-03-31 $455
2010-12-31 $470
2010-09-30 $466
2010-06-30 $508
2010-03-31 $538
2009-12-31 $551
2009-09-30 $575
2009-06-30 $565
2009-03-31 $596
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
Johnson & Johnson (JNJ) United States $373.591B 15.15
AbbVie (ABBV) United States $312.696B 16.46
Merck (MRK) United States $250.889B 16.67
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97